Alkermes (NASDAQ:ALKS) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Alkermes (NASDAQ:ALKS) in a report issued on Saturday. The firm issued a buy rating on the stock.

Other equities research analysts have also issued research reports about the stock. HC Wainwright reaffirmed a neutral rating and issued a $34.00 price objective on shares of Alkermes in a research note on Thursday, July 27th. UBS Group initiated coverage on shares of Alkermes in a research note on Tuesday, October 17th. They issued a neutral rating and a $31.00 price objective for the company. Piper Sandler reduced their price objective on shares of Alkermes from $37.00 to $35.00 and set an overweight rating for the company in a research note on Friday, October 27th. Mizuho reduced their price objective on shares of Alkermes from $37.00 to $35.00 and set a buy rating for the company in a research note on Thursday, October 26th. Finally, Evercore ISI raised shares of Alkermes from an in-line rating to an outperform rating in a research note on Tuesday, October 24th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of Moderate Buy and a consensus target price of $32.29.

Alkermes Trading Down 0.2 %

Alkermes stock opened at $24.18 on Friday. The company’s fifty day simple moving average is $26.81 and its 200-day simple moving average is $28.92. The company has a quick ratio of 2.53, a current ratio of 2.91 and a debt-to-equity ratio of 0.21. Alkermes has a 12 month low of $22.01 and a 12 month high of $33.71. The stock has a market cap of $4.04 billion, a P/E ratio of 19.50 and a beta of 0.62.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Wednesday, October 25th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.19. Alkermes had a net margin of 13.50% and a return on equity of 11.41%. The business had revenue of $380.94 million during the quarter, compared to analyst estimates of $366.18 million. As a group, sell-side analysts forecast that Alkermes will post 1.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Diversified Trust Co raised its position in shares of Alkermes by 29.9% during the third quarter. Diversified Trust Co now owns 40,844 shares of the company’s stock valued at $1,144,000 after buying an additional 9,412 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Alkermes by 10.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,461,246 shares of the company’s stock valued at $40,930,000 after buying an additional 133,357 shares during the last quarter. Creative Planning raised its position in shares of Alkermes by 29.2% during the third quarter. Creative Planning now owns 10,023 shares of the company’s stock valued at $281,000 after buying an additional 2,266 shares during the last quarter. GTS Securities LLC raised its position in shares of Alkermes by 27.6% during the third quarter. GTS Securities LLC now owns 38,106 shares of the company’s stock valued at $1,067,000 after buying an additional 8,243 shares during the last quarter. Finally, Morgan Stanley raised its position in shares of Alkermes by 79.5% during the third quarter. Morgan Stanley now owns 2,012,792 shares of the company’s stock valued at $56,378,000 after buying an additional 891,641 shares during the last quarter. Institutional investors and hedge funds own 95.21% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer.